Printer Friendly

T CELL SCIENCES RECEIVES NOTICE THAT A FUNDAMENTAL U.S. TCAR PATENT WILL ISSUE

 CAMBRIDGE, Mass., April 27 /PRNewswire/ -- T Cell Sciences, Inc. (NASDAQ: TCEL), announced today that it has received a notice of allowance from the U.S. Patent Office that a patent application claiming T cell antigen receptor (TCAR) beta chain inventions will issue as a patent. T Cell Sciences considers the patent that will issue to be a critical component of its expanding proprietary position in TCAR technology. TCAR technology is being used by T Cell Sciences to develop therapeutics for the treatment of autoimmune diseases including multiple sclerosis, Chron's disease and rheumatoid arthritis.
 "We believe the broad patent position we are building will be fundamental to product development in the TCAR area," said Alan W. Tuck, president and chief executive officer of T Cell Sciences. The issuance of this patent, which is exclusively licensed to the company, will bring to 15 the total number of U.S. TCAR patents, issued or allowed, in T Cell Sciences' TCAR patent portfolio.
 Mark Davis at Stanford University, a member of T Cell Sciences' Scientific Advisory Board, is an inventor on this allowed patent application. The claims that will issue in this patent cover nucleic acid sequences which encode fragments of the beta chain of the TCAR. T Cell Sciences now has exclusive rights to or owns multiple patents and patent applications covering nucleic acid, protein and antibodies relating to the alpha, beta, gamma and delta chains of the TCAR. Additional TCAR patent applications are pending worldwide which include protein fragments of the TCAR chains as well as therapeutic uses of TCARs.
 In January 1992 T Cell Sciences entered into a joint development arrangement with AB Astra, a multinational pharmaceutical company, to develop therapeutic products based on T Cell Sciences' proprietary position in TCAR technology. Product candidates for the treatment of multiple sclerosis and Chron's disease have been identified and are being developed under this program. In addition, basic research into the use of TCAR products for the treatment of autoimmune diseases is underway.
 T Cell Sciences has exclusive rights under two Omnibus license agreements covering TCAR inventions. The alpha and beta chain Omnibus license agreement covers the early 1980's pioneering alpha and beta TCAR chain inventions of Drs. Mark Davis and Irving Weissman, Stanford University; Dr. Tak Mak, Ontario Cancer Institute, Drs. Haruo Saito and Susumu Tonegawa, MIT; and Dr. Leroy Hood, California Institute of Technology. The gamma and delta chain Omnibus license agreement covers similar pioneering gamma and delta chain inventions of Drs. Michael Brenner and Jack Strominger, Dana-Farber Cancer Institute and Harvard University; Dr. Mark Davis, Stanford University; and Drs. Haruo Saito and Susumu Tonegawa, MIT.
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures, and markets innovative diagnostic and research products.
 -0- 4/27/93
 /CONTACT: Alan W. Tuck, president and chief executive officer or Susan Primrose, manager, market development & communications, 617-621-1400, both of T Cell Sciences, Inc./
 (TCEL)


CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU:

CH -- NE004 -- 1140 04/27/93 08:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:532
Previous Article:CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS
Next Article:BROOKTROUT TECHNOLOGY ANNOUNCES FAX AGREEMENT WITH NORTHERN TELECOM
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters